Key finding

Older patients with advanced or metastatic hormone-sensitive breast cancer show a 21% reduction in mortality risk when given cyclin-dependent kinase 4/6 (CDK4/6) inhibitors added to endocrine therapy versus endocrine therapy alone.

The 21% risk reduction is nearly identical to the magnitude of risk reduction in younger patients (aged ...